# Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

> **NCT06160791** · PHASE2 · RECRUITING · sponsor: **Jerry Lee, MD, MSc, MPhil** · enrollment: 36 (estimated)

## Conditions studied

- Hemophagocytic Lymphohistiocytoses

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Etoposide
- **DRUG:** Dexamethasone
- **PROCEDURE:** Non-interventional Imaging
- **PROCEDURE:** Research Biopsy
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT06160791
- **Lead sponsor:** Jerry Lee, MD, MSc, MPhil
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-11-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06160791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06160791, "Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06160791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*